Melanoma News

Looking Ahead With TIL Therapy in Melanoma and Beyond

Last year’s FDA approval of lifileucel (Amtagvi) for metastatic melanoma marks a pivotal moment for TIL (tumor-infiltrating lymphocytes) therapy, establishing it as the first cellular therapy for a solid tumor. This breakthrough signals a future where TIL therapy could extend beyond melanoma, offering hope for patients with other hard-to-treat cancers. Here, Anuradha Krishnamurthy, MBBS, medical oncologist at Roswell Park Comprehensive Cancer Center, discusses this exciting field.

Read More
MRV News
Melanoma News
Archive
Menu